Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

In a clinical trial, Fathi et al. show that a booster vaccination with a vector vaccine candidate against the highly pathogenic Middle East Respiratory Syndrome coronavirus is safe and strongly improves the immunity generated by primary immunization.

Bibliographic Details
Main Authors: Anahita Fathi, Christine Dahlke, Verena Krähling, Alexandra Kupke, Nisreen M. A. Okba, Matthijs P. Raadsen, Jasmin Heidepriem, Marcel A. Müller, Grigori Paris, Susan Lassen, Michael Klüver, Asisa Volz, Till Koch, My L. Ly, Monika Friedrich, Robert Fux, Alina Tscherne, Georgia Kalodimou, Stefan Schmiedel, Victor M. Corman, Thomas Hesterkamp, Christian Drosten, Felix F. Loeffler, Bart L. Haagmans, Gerd Sutter, Stephan Becker, Marylyn M. Addo
Format: Article
Language:English
Published: Nature Portfolio 2022-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-31557-0

Internet

https://doi.org/10.1038/s41467-022-31557-0

Similar Items